Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3rd Q $750K to $900K
Some posts are just amazing 3rd Q numbers Nov. 15, 2021
Yes that is correct and should be plus that
?????? What is the story???????/
Let the good times roll on Biel about time for a move.
Would have to have a link to the chicken shit post about Q3 sales or it would have to be a really cold day in hell before I would come close to believing anything in the post related to Biel
Humm? CVS stores close to Canton, Ga Stock of KT Recovery Wave
Out of stock
129 Marietta Highway
Canton, GA 30114
1.0 mi
Out of stock
2022 Cumming Hwy
Canton, GA 30115
3.1 mi
Low stock
3785 Sixes Rd, Corner Of Bells Ferry Road
Canton, GA 30114
4.7 mi
Low stock
6120 Hickory Flat Hwy.
Canton, GA 30115
6.7 mi
Low stock
1600 Town Lake Parkway
Woodstock, GA 30189
9.3 mi
Out of stock
140 Woodstock Square Ave
Woodstock, GA 30189
10.8 mi
Low stock
4595 Highway 92
Acworth, GA 30102
11.7 mi
Out of stock
1135 Woodstock Rd
Roswell, GA 30075
13.7 mi
Low stock
1380 Woodstock Rd
Roswell, GA 30075
13.7 mi
Out of stock
3513 Baker Rd., Ste. 500
Acworth, GA 30101
13.9 mi
Low stock
12070 Crabapple Road
Roswell, GA 30075
14.1 mi
Low stock
3051 Sandy Plains Road
Marietta, GA 30066
14.8 mi
Out of stock
3930 Shallowford Road Ne
Marietta, GA 30062
14.9 mi
Low stock
100 Piedmont Rd.
Marietta, GA 30066
15.7 mi
Low stock
13933 Alpharetta Hwy.
Milton, GA 30004
16.1 mi
Low stock
11710 Alpharetta Hwy
Roswell, GA 30076
16.1 mi
Out of stock
740 Ernest W Barrett Pkwy Nw
Kennesaw, GA 30144
16.2 mi
Out of stock
5740 Atlanta Highway
Alpharetta, GA 30004
16.2 mi
Low stock
2782 North Cobb Parkway
Kennesaw, GA 30152
16.3 mi
Low stock
965 Joe Frank Harris Pkwy Se
Cartersville, GA 30120
16.4 mi
Out of stock
184 North Main Street
Alpharetta, GA 30009
16.4 mi
Out of stock
266 East Church St
Jasper, GA 30143
16.6 mi
Low stock
4895 Post Rd.
Cumming, GA 30040
16.8 mi
Out of stock
13055 Hwy 9 N
Milton, GA 30004
16.9 mi
Low stock
13 North Tennessee St.
Cartersville, GA 30120
16.9 mi
NO, just another misleading pig shit post related to Biel
LMAO-Pain-Cream-What A Load Of Ant Shit Biel Is Selling Pain Relief And Healing.
ActiPatch A non-invasive and medication-free method of managing pain is using the electroceutical device ActiPatch. The device works by emitting electromagnetic signal pulses into whichever area you are experiencing pain, roughly 1000 pulses each second, stimulating your nerve neuromodulation to reduce pain sensations. It does all this without producing a vibrating or uncomfortable feeling, so is truly unobtrusive.
Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens
BioElectronics-Corporation-Revenue-Growth-Exceeds-665% Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, that amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
LMFAO link to Best Sellers in Pain Relief Homeopathic Remedies, Really GEEEZZZ
Laugh My Fricken Ass Off
Sales-Trac-Rate-Biel-1st-Half-Of-2021-Sales Increase Of 665% #1
Q2 2021 sales do not account for deferred revenue from booked orders, which amounts to $555,000. Paid for but not shipped, yet. Over $900,000 in sales with deferred sales for Q2
BIEL Q1 & Q2 SALES Over $1 Million
BIEL-Q2/2021-Financials-Revenue-Growth-Exceeds-665%
BioElectronics-Corporation-Revenue-Growth-Exceeds-665% Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, that amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
Would have to be paid for info service related to Biel
Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
BioElectronics-Corporation-Revenue-Growth-Exceeds-665% Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, that amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
BioElectronics-Corporation-Revenue-Growth-Exceeds-665%
Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like to clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World-class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, which amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (the Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
LMAO POST IS Full Of PIG Crap Related To Biel
BioElectronics-Corporation-Revenue-Growth-Exceeds-665% Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, that amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
PRESS RELEASE FOR MONDAY, AUGUST 30, 2021
BioElectronics Corporation Discusses Q2 Financials
Revenue Growth Exceeds 665%
FREDERICK MARYLAND, August 30, 2021 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials.
Key facts from the Q2 financials many of which were found in the footnotes:
• The CEO again took no pay, and the Chairman invested additional cash into the Company.
• Two major lenders neither collected nor accrued interest on their notes.
• No additional stock was issued during the 2nd quarter.
• Products using BIEL technology are now on the shelves of major retailers including CVS and Walgreens.
• World class athletes are actively promoting BIEL’s technology (KT Recovery+ Wave) on social media.
Keeping in line with BIEL’s impressive year-over-year growth, the six months ended June 30, 2021 sales were 665% higher than the same period during 2020. While Q2 2021 sales were lower than Q1 2021 sales, this does not account for deferred revenue from booked orders, that amounts to $555,000. Deferred revenue will be recorded as sales in the applicable quarter when the products are shipped.
BioElectronics is working to accommodate additional orders after strong product launches in Q1 2021 by their three major channel partners: KT Health, Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market. Consumer acceptance of the technology has been very positive, as witnessed by strong consumer reviews for the KT Recovery+ Wave™ & DonJoy® EME powered by ActiPatch® (averaging over 4.5/5 on Amazon.com and their respective company websites). Feedback from surgeons for the RecoveryRx® has been excellent.
The Company is also making progress on international sales. In addition to re-acquiring the CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which allows for product distribution in Canada, Australia, and New Zealand. Leveraging these clearances, and working through Medi-Launch, the Company signed four new international distributorship contracts for its RecoveryRx line. The sales team is in ongoing discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region.
The U.S. Securities and Exchange Commission recently announced that in September it will no longer allow the trading of “Pink No Information” and “Grey Market” stocks. Since BIEL reports on OTC Markets (https://www.otcmarkets.com/stock/BIEL/overview) and is up-to-date on its filings, the new SEC mandate does not impact BIEL.
Finally, the Company has received notification from the Small Business Administration, that the 2nd Payroll Protection Program Loan has also been forgiven in full. The Company will recognize this forgiveness of debt as “Other Income” during the 3rd quarter.
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
OTCMARKETS.COM
www.otcmarkets.com
Negative nanny post related to Biel mean nothing to me
Owners of KT Tape Palladin Consumer Retail Partners (“PCRP” or “Palladin”) is a Boston-based private investment firm, founded in 1998 as Palladin Capital Group, that focuses primarily on the retail and consumer products sectors in North America and Europe. Our team has a strong investment and operating track record; the Principals of PCRP have invested in, financed, or managed over 100 public and private retail and consumer products companies. We pride ourselves on working closely with management teams to create value through strategic and operational initiatives. PCRP strives to provide its portfolio companies with the advantages of a strategic partner and the operating flexibility and incentives of a financial investor.
PCRP targets middle market retail and consumer products companies with revenues ranging from $50 to $500 million. We seek to invest $10-$50 million of equity capital in each transaction, but will call on our investment partners for larger opportunities.
https://pcrp.com/overview/
All Wrapped Up: Palladin Consumer Acquires Maker of KT Tape
Updated Jan. 23, 2014 4:54 pm ET
Palladin Consumer Retail Partners said it acquired KT Health LLC, a maker of kinesiology tape and related sports medicine products.
Terms of the transaction weren't disclosed. Palladin Consumer Retail Partners, previously known as Palladin Capital Group, invests $10 million to $50 million of equity capital in retail and consumer products companies with annual revenue of $50 million to $500 million.
That figure is A Modelled Value, therefore, is a statistically derived estimation rather than an actual figure. In GRS modelling is only used when no actual figure is available. Guessing for a private company.
Just an opinion in the post related to Biel, NO FAcTS
Walmart has 15 sellers on their .com website selling the KT-Recovery-Wave a Biel Product
https://www.walmart.com/product/641183698/sellers
Next Week Go Biel Run Coming
Replying to a post that does not agree with your position on BIEL is a Wasted post that could be used to support Biel.
Actipatch SAME TECHNOLOGY.
NEW BRAND PARTNER & RETAIL DISTRIBUTION.
Now at your local
CVS Pharmacy
Now Available at:
cvs-pharmacy
Available online or in stores at CVS Pharmacy!
Item SKU# 665724
Funny pig crap posted related to Biel, nothing but misleading false info.
GO BIEL
The post related to Biel is nothing but pure rubbish
LOL some post related to BIEL are just pure PIG CRAP
BioElectronics (OTC: BIEL) Management Answer to Shareholder Who Asked about News Releases:
As we have repeatedly stated, management is not going to issue “fluff” press releases to hold up the stock price. We will make material news announcements only via press releases when appropriate.
We have held the line on dilution by staying out of the equity market for working capital. We have products on shelf in CVS stores nationwide less than a year after receiving the general musculoskeletal pain clearance from the US FDA- in the midst of a global pandemic. We have KT Health actively promoting the technology. We are shipping products both domestically and internationally. Both St. John’s and Ibex LLC have forgone all interest collection for both 2020 and 2021 (more than $1.5 million) to move the Company towards profitability as quickly as possible. Keith Nalepka, Rick Staelin, and Kelly Whelan have all invested additional cash in the Company in the last 6 months. We believe in our plan. There is no lack of progress. Unfortunately, we have some people out there who are set on harming the Company’s share price with constant negative speculation.
We are all working to increase revenue quarter over quarter. The share price will take care of itself as revenue increases.
Thank you for being a shareholder. We appreciate the support.
Release #:812-205449-rl-1141231:
pknopick@eandecommunications.com
Waste of time replying to BS fake info